We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2026
SHIVALIK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shivalik Rasayan Limited reported audited financial results for FY2026 ending March 31. Standalone revenue grew 14% to Rs 17,023 lakhs, while consolidated revenue increased 18% to Rs 36,800 lakhs driven by pharma formulation segment. However, standalone net profit declined significantly to Rs 817 lakhs from Rs 1,387 lakhs (down 41%), and consolidated net profit fell to Rs 1,797 lakhs from Rs 2,042 lakhs (down 12%). The Board recommended a 10% dividend (Rs 0.50 per share) subject to shareholder approval. Mr. Sanjay Bansal resigned as Non-Executive Director. M/s Arun Agarwal & Co was appointed as new Internal Auditor replacing M/s Amar Sharma & Co, and M/s Cheena & Associates appointed as Cost Auditor. The statutory auditors issued an unmodified (clean) opinion.
Despite healthy revenue growth, profit decline indicates cost pressures or operational challenges. The clean audit opinion and dividend recommendation are positives, but the profit contraction may concern investors. The resignation of a director and internal auditor change adds governance movement to monitor.